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Iowa
Board of Pharmacy
Executive Director Position
Members of the Iowa Board of Pharmacy and Board staff have 
been diligently searching for a successor for Lloyd K. Jessen, JD, 
RPh, who retired from the executive director position in March 
2015 after nearly 30 years of dedicated service to the Board. By the 
time this Newsletter is distributed, the Board hopes to have named 
a new executive director for the Board. Please check the Board’s 
website (www.iowa.gov/ibpe) for further information.
Pharmacy Compounding for Office Use
Under the federal Drug Quality and Security Act, signed into law 
in November 2013, only a pharmacy that registered with Food and 
Drug Administration (FDA) as an outsourcing facility is allowed 
to provide compounded, non-patient-specific drug products (for 
human use) to another health care provider to be administered in 
the prescriber’s office. If your pharmacy is not an FDA-registered 
outsourcing facility, you may not sell compounded non-patient-
specific drug products to a prescriber for office administration. 
Your pharmacy may compound and provide drug products to a 
prescriber, but only after your pharmacy has received a patient-
specific prescription for the product. Your pharmacy may perform 
bulk compounding in anticipation of the needs of a prescriber 
based on historical dispensing, but the compounded product may 
not be delivered to the prescriber’s office until a patient-specific 
prescription for the product is received by the pharmacy. As this is 
a federal law, the Board may not grant a waiver of compliance with 
the law. Also, be reminded that pharmacies may only compound 
drugs that are not copies of commercially available drugs. For a 
compounded product that is essentially a copy of a commercially 
available product, the compounded product must have a change that 
produces, for that specific patient, a clinically significant differ-
ence to meet a medical need as determined and authorized by the 
prescriber. The laws regarding compounding and compounding 
for office use are still evolving, so be sure to check the Board’s 
website for updates.
Drug Wholesalers and Reverse Distributors
Most Iowa pharmacies today have a primary wholesaler and 
one or more secondary wholesalers that the pharmacy uses to 
replenish their inventories. All wholesalers who do business in 
Iowa, whether a supplier or a reverse distributor, must maintain 
an Iowa wholesale drug license. While most primary wholesalers 
are known nationwide and their Iowa license status is typically up 
to date, it is important for an Iowa pharmacy to know for sure that 
any secondary wholesalers or reverse distributors used are licensed 
in Iowa. A pharmacy can verify a license on the Board’s website 
at www.state.ia.us/ibpe/verification.html or contact the wholesaler 
or reverse distributor directly and request a copy of its assigned 
Iowa wholesaler license.
Web-Based Marketplaces
In recent years, the web-based marketplace has been an avenue 
for independent pharmacies to purchase and sell small quantities 
of non-controlled, unexpired medications to licensed pharmacies 
in Iowa or other states. The marketplace has also been an avenue 
for licensed pharmacies in Iowa to obtain medication for short-
term patient needs from other licensed pharmacies in Iowa or 
other states. These are direct pharmacy-to-pharmacy transactions 
administered or facilitated by the web-based marketplace. Iowa 
pharmacy law allows Iowa-licensed pharmacies to sell medica-
tions, at wholesale, to other licensed pharmacies within or outside 
Iowa as long as the total of such sales does not exceed 5% of the 
pharmacy’s gross annual sales of prescription products. An Iowa-
licensed pharmacy that sells or acquires medications to or from an 
out-of-state pharmacy must ensure that the laws of the out-of-state 
pharmacy’s home state allow the transaction.
Ensuring Timely License/Registration 
Renewals
Although license and registration renewal applications are al-
ways mailed at least two months prior to expiration of the license or 
registration, it seemed that more renewal applications were submit-
ted to the Board office for processing in the last week and even the 
day before their June expiration than the Board has experienced in 
past years. Subsequently, more individuals were adversely affected 
because their renewals could not be processed before expiration, 
resulting in their inability to practice or work. Board staff prides 
itself on efficient and timely processing of license and registration 
renewals, but during certain times of the year and including the last 
week of each month, processing may be delayed due to increased 
volume. Processing a new registration application or a license 
renewal application may take two to three weeks (including mail 
time) before you receive an updated certificate. So keep in mind 
that if you submit or deliver your renewal application on the date 
of expiration, you will avoid paying a penalty fee for late renewal, 
but you will not have an unexpired certificate of license or registra-
tion authorizing continuing practice after expiration. The same is 
true for pharmacies and drug wholesalers. If you want to ensure 
authority to continue operating after December 31, please submit 
completed renewal applications no later than the second week in 
December. And before submitting any application to the Board, 
review the application to be sure nothing has been omitted and no 
question has been left unanswered. Incomplete applications will 
delay the renewal process at least two weeks.
ISMP has been reflecting on the strength and resolve of many 
across the nation who have demonstrated an unparalleled commit-
ment to keeping patients safe. Despite the many safety accomplish-
ments in 2014, ISMP cannot help but mull over persistent medication 
safety gaffes that continue to be unresolved. ISMP would like to share 
seven persistent safety gaffes of 2014, in three parts, with NABP 
National Pharmacy Compliance News readers with the hope that 
they will join ISMP in bringing attention to these crucial issues and 
the compelling need for their resolution. Part one of the three-part 
series is below.
1) Patient Counseling: Still Only a Veiled “Offer” in Many States
The effectiveness of patient counseling in a community pharmacy 
to detect and prevent medication errors, and its link to improved 
medication adherence and positive clinical outcomes have been well 
documented in the literature. Yet, studies have placed patient counsel-
ing rates at only eight percent to 42%. An increase in the frequency 
and quality of patient counseling has been linked to state-specific 
regulations that require patient counseling for new prescriptions 
coupled with strict enforcement surveillance. States that require an 
“offer” to counsel have very low patient counseling rates. Patients 
often fail to recognize an offer to counsel when simply asked, “Do 
you have any questions?” or told to “Please sign here.” They may 
not even know what to ask. This means that, with few exceptions, 
pharmacies in states that require only an offer to counsel will likely 
dispense a powerful opioid such as fentanyl transdermal patches and 
allow the patient or caregiver to walk out of the pharmacy without 
even a brief discussion about safe use and disposal. ISMP has long 
promoted mandatory patient counseling in community pharmacies 
for prescriptions for targeted high-alert medications.
For a list of high alert community medications, please visit 
www.ismp.org/communityRx/tools/ambulatoryhighalert.asp. ISMP 
hopes you will use this list to determine which medications require 
mandatory patient education in order to reduce the risk of errors and 
minimize harm.
2) Patients Impacted by Dispensing Errors: Callous Response 
From Pharmacists
When patients report dispensing errors to ISMP, they are usually 
more upset about the response they received when contacting the 
pharmacist or pharmacy manager than the actual error itself. All too 
often, consumers tell ISMP that pharmacy staff have responded in a 
callous manner when confronted with the possibility of a dispensing 
error, demonstrating a lack of empathy and concern for the adverse 
effects the patient might have experienced. While pharmacy staff may 
want to be more responsive to patients who report errors, they are 
often following corporate policies that are focused on legal concerns. 
As patients are continually encouraged to be active participants in 
their health care, they want and deserve honest disclosure of errors, 
and knowledge that there is an action plan to reduce the risk of it 
happening again.
Flurbiprofen-Containing Topical Medication May 
Be Dangerous to Pets, Cautions FDA
People who use topical medications containing flurbiprofen, a 
nonsteroidal anti-inflammatory drug (NSAID), should take care to 
prevent their pets from being exposed to the drug, recommended FDA 
in an April 2015 Safety Alert. The warning is in response to reports 
of cats in two separate households that became ill or died after their 
owners used topical medications containing flurbiprofen to treat 
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Counterfeit Botox Found in the United States, 
FDA Warns
On April 16, 2015, Food and Drug Administration (FDA) 
alerted health care providers that a counterfeit version of Botox® 
was found in the United States and may have been sold to doctors’ 
offices and clinics throughout the country. The counterfeit products 
may be identified by a missing lot number on the vial, missing 
information on the carton (next to LOT, MFG, and EXP), and a 
displayed active ingredient as “Botulinum Toxin Type A” instead of 
“OnabotulinumtoxinA.” The counterfeit products were sold by an 
unlicensed supplier who is not authorized to ship or distribute drug 
products in the US, according to an FDA Drug Safety Alert. The 
agency advises health care providers to confirm that the distributor 
from which they purchase Botox is authorized by Allergan, the drug’s 
manufacturer. No adverse events related to this product have been 
reported to FDA.
Medical practices that purchase and administer counterfeit, illegal, 
and unapproved medications from unlicensed or foreign sources are 
putting patients’ health at risk, as patients may not be getting proper 
treatment, warns FDA. Wholesale drug distributors must be licensed 
in the states where they conduct business. Suspicious Botox products 
may be reported to FDA’s Office of Criminal Investigations. More 
information is available on the FDA website at www.fda.gov/Drugs/
DrugSafety/ucm443217.htm.
One way pharmacies can be assured of the legitimacy of a whole-
sale distributor is to look for the National Association of Boards of 
Pharmacy® (NABP®) Verified-Accredited Wholesale Distributors® 
(VAWD®) Seal. Wholesale distributors that achieve VAWD accredita-
tion are in compliance with state and federal laws, as well as NABP’s 
VAWD criteria. Wholesale distributors that display the VAWD Seal 
as part of their accreditation have undergone a criteria compliance 
review, including a rigorous review of their operating policies and 
procedures, licensure verification, survey of facility and operations, 
background checks, and screening through the NABP Clearinghouse. 
Accredited facilities are reviewed annually and undergo an on-site 
survey every three years. Created in 2004, the accreditation program 
plays a pivotal role in preventing counterfeit drugs from entering the 
US drug supply.
Seven Persistent Safety Gaffes in Community/
Ambulatory Settings That Need to Be Resolved!
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP is 
an independent nonprofit agency and federally 
certified patient safety organization that analyzes medication errors, 
near misses, and potentially hazardous conditions as reported by 
pharmacists and other practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gathers expert opinion 
about prevention measures, and publishes its recommendations. 
To read about the risk reduction strategies that you can put into 
practice today, subscribe to ISMP Medication Safety Alert!® 
Community/Ambulatory Care Edition by visiting www.ismp.org. 
ISMP provides legal protection and confidentiality for submitted 
patient safety data and error reports. Help others by reporting actual 
and potential medication errors to the ISMP National Medication 
Errors Reporting Program Report online at www.ismp.org. Email: 
ismpinfo@ismp.org.
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muscle, joint, or other pain. Two cats in one household developed kid-
ney failure and recovered with veterinary care. Two cats in a second 
household developed symptoms that included reluctance to eat, leth-
argy, vomiting, melena, anemia, and dilute urine, and subsequently 
died despite veterinary care. A third cat in the second household also 
died after the owner stopped using the medication. Necropsies on the 
three cats found evidence that were consistent with NSAID toxicity. 
The pet owners had applied the drug to their own neck or feet, and not 
directly to the pet, and it is not known exactly how the cats became 
exposed to the medication, the Safety Alert notes.
Health care providers who prescribe or dispense topical pain 
medications containing flurbiprofen should advise patients with 
pets to take steps to prevent exposure of the pets to the medication. 
Additional information is available in the FDA Safety Alert available 
at www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlerts 
forHumanMedicalProducts/ucm443386.htm.
New FDA Drug Info Rounds Videos Available
FDA Drug Info Rounds, a series of online videos, provides im-
portant and timely drug information to practicing clinical and com-
munity pharmacists so they can help patients make better decisions. 
The latest Drug Info Rounds videos are as follows.
 ♦ In “NDC Directory,” pharmacists demonstrate how to use this 
quick, easy, online resource.
 ♦ In “FAERS,” pharmacists discuss the FDA Adverse Event Re-
porting System (FAERS) and review three ways FAERS data 
is made available to the public. 
Drug Info Rounds is developed with contributions from pharma-
cists in FDA’s Center for Drug Evaluation and Research, Office of 
Communications, Division of Drug Information. These videos and 
previous Drug Info Rounds resources are available on the FDA web-
site at www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ 
ucm211957.htm.
Mucinex Cold, Sinus, and Flu Medications 
Recalled Due to Possible Labeling Error
In April 2015, RB (formerly Reckitt Benckiser) of Parsippany, 
NJ, issued a voluntary recall of certain lots of liquid Mucinex® due 
to a potential error involving the over-the-counter medications’ drug 
facts labels. While the front label of the recalled lots correctly lists the 
name of the product as well as the active ingredients, some bottles 
may not have the correct corresponding drug facts label on the back. 
The recall was initiated after a confirmed report from a retailer. The 
recalled medications include:
 ♦ MUCINEX FAST-MAX Night-Time Cold & Flu;
 ♦ MUCINEX FAST-MAX Cold & Sinus;
 ♦ MUCINEX FAST-MAX Severe Congestion & Cough; and
 ♦ MUCINEX FAST-MAX Cold, Flu & Sore Throat.
If mislabeled, consumers who purchase these products may be 
unaware of the side effects and potential risks associated with active 
ingredients such as acetaminophen, dextromethorphan, guaifenesin, 
phenylephrine, and/or diphenhydramine. RB is recalling these 
products as a precautionary measure to ensure consumers have all 
relevant facts and warnings; the company asks consumers to dispose 
of any unused product.
Additional information about the recall, including the lot numbers 
and expiration dates for the recalled medications and guidelines for 
safe disposal, is available on the FDA website at www.fda.gov/Safety/
Recalls/ucm444028.htm.
Pharmacists Are Performing More Patient Care 
Activities, National Survey Indicates
Pharmacists are performing more patient care activities in a va-
riety of health care settings and are spending less time in traditional 
dispensing roles, indicates the 2014 National Pharmacist Workforce 
Survey. Specifically, the report found that 60% of pharmacists 
provided medication therapy management, and 53% performed 
immunizations in 2014, indicates a press release from the American 
Association of Colleges of Pharmacy (AACP). The survey was 
created using a random sample of 5,200 individuals selected from 
a list of 7,000 licensed pharmacists in the US. Response rate to the 
survey was 48%.
Additional details, including the full results of the survey and an 
executive summary, are available through the Resources section of 
the AACP website, www.aacp.org.
Potentially Lethal Drug Sold Globally as Diet 
Supplement, Warns INTERPOL
INTERPOL has issued a global alert for a drug known as 
2.4-dinitrophenol (DNP), an illicit and potentially lethal drug sold as 
a dieting and body building aid. The “Orange Notice” warning about 
DNP was published in May 2015, following the death of a woman 
in the United Kingdom and the serious illness of a man in France. In 
the 1930s, DNP was used to boost metabolism and encourage weight 
loss, but it was taken out of circulation due to several deaths. Sold 
as a plain yellow powder, capsules, or cream, DNP is often illegally 
manufactured and sold via the Internet; unsafe manufacturing of the 
drug and potential contamination may be magnifying the dangers of 
taking the drug, notes INTERPOL.
Additional information is available on the INTERPOL website at 
www.interpol.int/News-and-media/News/2015/N2015-050.
HHS Announces New Interactive Training on 
Safe Opioid Use
The Department of Health and Human Services (HHS) has 
announced a new, interactive training course that teaches health 
care providers how to talk to patients about safely using opioids to 
manage chronic pain. The course, “Pathways to Safer Opioid Use,” 
also teaches implementation strategies for meeting the opioid-related 
recommendations from the National Action Plan for Adverse Drug 
Event Prevention. Adverse drug events (ADEs) are the largest 
contributor to hospital-related complications and account for more 
than 3.5 million physician office visits each year, according to 
HHS. The training, which is offered at no cost, includes self-guided 
interactive videos with decision points to help users learn how to 
apply health literacy strategies to help patients understand and act on 
information to prevent opioid-related ADEs; identify individual risk 
factors, opioid medications, and interactions that place individuals 
with chronic pain at increased risk for opioid-related ADEs; recognize 
the importance of a multidisciplinary team-based approach to 
treating patients with chronic pain; and demonstrate the ability to 
combine the principles of the Health Literate Care Model and the 
biopsychosocial model.
Additional information, including a link to the National Action 
Plan for Adverse Drug Event Prevention, is available on the course 
website at http://health.gov/hcq/training.asp#pathways.
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Record Maintenance
The Board’s compliance officers have recently learned that a 
wholesale distributor is recommending that pharmacies store records 
inconsistent with the Board’s rules. The Board requires a pharmacy 
to maintain records in the original format received. If the record is 
originally received in hard copy format, the hard copy record must be 
retained for the required length of time. The pharmacy may choose 
to maintain an alternate format (such as scanning for an electronic 
record), but that may not replace the original format as required by 
Board rule. For example, when a pharmacy receives a prescription 
via electronic prescribing, the pharmacy must maintain the original, 
electronic record for two years from the last date of dispensing. The 
pharmacy may choose to also generate a hard copy record, but this 
is not required and cannot replace the maintenance of the electronic 
record. Likewise, when a pharmacy receives a hard copy invoice for 
drugs received, it may choose to scan the document into an electronic 
record, but the pharmacy must still maintain the original hard copy 
invoice for the period of time required under pharmacy law and rules.
New Statewide Rules Tracking and  
Comment Site
A new state website, https://rules.iowa.gov, allows Iowans to 
view administrative rules that are open for comment, comment on 
rules online, find contact information for each specific rule, learn 
how much longer the comment period is open, and inquire about 
the administrative rule process. The new website creates a one-stop 
shop for viewing rules and commenting on proposed rules of inter-
est. Members of the public have a minimum of 20 days to comment 
on a rule from the date the proposed rule is published. Comments 
may be submitted directly to the contact person identified in the 
proposed rule or comments may be submitted on the website. Com-
ments submitted on the website are routed to the contact person 
identified in the specific proposed rule. The website was built and 
is maintained by the Iowa Office of the Chief Information Officer.
Regulatory Plan for Fiscal Year 2016
The Board has identified nine regulatory subjects and issues, 
including telepharmacy, controlled substances collection and 
disposal, wholesale drug licenses, nuclear pharmacy practice, 
nonresident pharmacies, and long-term care pharmacy practice, for 
discussion, review, and possible rulemaking or rule revision during 
this fiscal year (July 2015 through June 2016). As always, the Board 
welcomes comments, suggestions, and objections to any current 
or proposed rules. The regulatory plan is available on the Board’s 
website under Rules/Laws. Note that the dates under “Schedule 
for Action” are estimates and will be adjusted as needed. Please 
watch for information on these subjects in the coming months. 
The address for the current Board website is www.iowa.gov/ibpe.
Coming Soon! Redesigned Board Website
Many of you may have noticed that it has been a few years since 
any substantive changes or improvements have been made to the 
Board’s website. That will soon change. Debbie Jorgenson, admin-
istrative assistant and webmaster for the Board, has been working 
on a website redesign with new features and a new, fresher look. 
The Board believes the redesigned website will improve the Board’s 
ability to showcase items of interest and concern to Board licensees, 
registrants, and the public, and will provide more prominent and 
timely notification regarding important issues. The new website 
design is compatible with cell phone and tablet use and display, and 
will also provide the functional base for the eventual capability for 
online license renewal. Unveiling of the new website is planned 
for October 2015. Please check out the new website that will be 
available at a new address: www.iowa.gov/pharmacy.
Email List Service Available
To receive email notifications regarding items of timely impor-
tance, including notices of proposed and new laws and rules, please 
subscribe to the Board’s email list service. Subscribing is easy and 
painless – all that is needed is your email address. Scroll to the bot-
tom of any page on the Board’s website, enter your email address, and 
click “Subscribe.” You will receive an email asking you to respond, 
confirming your subscription. Reply to the email to complete your 
subscription. The email list is used for official Board communica-
tions only, and your email address will not be shared or disclosed to 
others. You can unsubscribe at any time by following the instructions 
at the bottom of any email received through the list service.
Follow the Board on Facebook and Twitter
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/IABoardPharmacy
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